Treatment of breast cancer
View Patent ↗The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
1. A method of treating triple negative breast cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of
2. The method of claim 1 , wherein the compound is enzalutamide:
3. The method of claim 1 , wherein the triple negative breast cancer is a subtype selected from the group consisting of basal-like type 1 (BL1), basal-like type 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) subtypes.
4. The method of claim 1 , wherein cells of the triple negative breast cancer comprise a BRCA1 mutation.
5. The method of claim 1 , wherein the triple negative breast cancer comprises cells that do not express detectable androgen receptor.
6. The method of claim 1 , wherein the triple negative breast cancer comprises cells that express an androgen receptor.
7. The method of claim 1 , further comprising administering to the patient a second therapeutic treatment.
8. The method of claim 3 , wherein the triple negative breast cancer is the BL1 subtype.
9. The method of claim 3 , wherein the triple negative breast cancer is the BL2 subtype.
10. The method of claim 3 , wherein the triple negative breast cancer is the IM subtype.
11. The method of claim 3 , wherein the triple negative breast cancer is the M subtype.
12. The method of claim 3 , wherein the triple negative breast cancer is the MSL subtype.
13. The method of claim 3 , wherein the triple negative breast cancer is the LAR subtype.
14. The method of claim 4 , wherein the compound is enzalutamide.
15. The method of claim 5 , wherein the compound is enzalutamide.
16. The method of claim 6 , wherein the compound is enzalutamide.
17. The method of claim 7 , wherein the compound is enzalutamide.
18. The method of claim 8 , wherein the compound is enzalutamide.
19. The method of claim 9 , wherein the compound is enzalutamide.
20. The method of claim 10 , wherein the compound is enzalutamide.
21. The method of claim 11 , wherein the compound is enzalutamide.
22. The method of claim 12 , wherein the compound is enzalutamide.
23. The method of claim 13 , wherein the compound is enzalutamide.